| Autophagy promotes MHC class II presentation of peptides from intracellular source proteins J Dengjel, O Schoor, R Fischer, M Reich, M Kraus, M Müller, K Kreymborg, ... Proceedings of the National Academy of Sciences 102 (22), 7922-7927, 2005 | 786 | 2005 |
| Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 Z Skrott, M Mistrik, KK Andersen, S Friis, D Majera, J Gursky, T Ozdian, ... Nature 552 (7684), 194-199, 2017 | 604 | 2017 |
| Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events S Arastu-Kapur, JL Anderl, M Kraus, F Parlati, KD Shenk, SJ Lee, ... Clinical Cancer Research 17 (9), 2734-2743, 2011 | 533 | 2011 |
| Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos, J Bladé, MV Mateos, ... Blood, The Journal of the American Society of Hematology 118 (17), 4519-4529, 2011 | 465 | 2011 |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and … M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468, 2020 | 326 | 2020 |
| Proteases involved in MHC dass II antigen presentation JA Villadangos, RAR Bryant, J Deussing, C Driessen, ... Immunological reviews 172 (1), 109-120, 1999 | 318 | 1999 |
| Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer F Berner, D Bomze, S Diem, OH Ali, M Fässler, S Ring, R Niederer, ... JAMA oncology 5 (7), 1043-1047, 2019 | 311 | 2019 |
| Multiple myeloma: patient outcomes in real‐world practice K Yong, M Delforge, C Driessen, L Fink, A Flinois, S Gonzalez‐McQuire, ... British journal of haematology 175 (2), 252-264, 2016 | 309 | 2016 |
| Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages GP Shi, RAR Bryant, R Riese, S Verhelst, C Driessen, Z Li, D Bromme, ... The Journal of experimental medicine 191 (7), 1177-1186, 2000 | 297 | 2000 |
| Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells C Driessen, RAR Bryant, AM Lennon-Duménil, JA Villadangos, ... The Journal of cell biology 147 (4), 775-790, 1999 | 291 | 1999 |
| European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma M Engelhardt, E Terpos, M Kleber, F Gay, R Wäsch, G Morgan, M Cavo, ... haematologica 99 (2), 232, 2014 | 273 | 2014 |
| Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG) H Schulz, U Rehwald, F Morschhauser, T Elter, C Driessen, T Rüdiger, ... Blood, The Journal of the American Society of Hematology 111 (1), 109-111, 2008 | 245 | 2008 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 194 | 2021 |
| Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German … U Rehwald, H Schulz, M Reiser, M Sieber, JO Staak, F Morschhauser, ... Blood, The Journal of the American Society of Hematology 101 (2), 420-424, 2003 | 192 | 2003 |
| Induction of cytokines by zinc ions in human peripheral blood mononuclear cells and separated monocytes. C Driessen, K Hirv, L Rink, H Kirchner Lymphokine and cytokine research 13 (1), 15-20, 1994 | 191 | 1994 |
| Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 … C Mamot, D Klingbiel, F Hitz, C Renner, T Pabst, C Driessen, U Mey, ... Journal of clinical oncology: official journal of the American Society of …, 2015 | 184 | 2015 |
| Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis E Tolosa, W Li, Y Yasuda, W Wienhold, LK Denzin, A Lautwein, ... The Journal of clinical investigation 112 (4), 517-526, 2003 | 176 | 2003 |
| Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells T Rückrich, M Kraus, J Gogel, A Beck, H Ovaa, M Verdoes, HS Overkleeft, ... Leukemia 23 (6), 1098-1105, 2009 | 163 | 2009 |
| Cathepsin S and an asparagine‐specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro H Beck, G Schwarz, CJ Schröter, M Deeg, D Baier, S Stevanovic, E Weber, ... European journal of immunology 31 (12), 3726-3736, 2001 | 155 | 2001 |
| Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism GP Soriano, L Besse, N Li, M Kraus, A Besse, N Meeuwenoord, J Bader, ... Leukemia 30 (11), 2198-2207, 2016 | 148 | 2016 |
